XML 127 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Reporting
12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
We operate in one business segment which focuses on applying our technology platforms to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.
Our revenue is derived primarily from customers in the pharmaceutical and biotechnology industries. Revenue from UCB Pharma, Takeda, and AstraZeneca represented 28%, 19% and 17% of our revenue, respectively, for the year ended December 31, 2019. Revenue from BMS represented 89% of our revenue, for the year ended December 31, 2018. Revenue from Lilly and UCB Pharma represented 42% and 12% of our revenue, respectively, for the year ended December 31, 2017.
Revenue by geographic area is based on the headquarters or shipping locations of our partners. The following table sets forth revenue by geographic area (in thousands):
 
Year Ended December 31,
 
2019
 
2018
 
2017
United States
$
27,093

 
$
1,090,794

 
$
190,810

Rest of World
87,524

 
102,529

 
116,901

Total revenue
$
114,617

 
$
1,193,323

 
$
307,711


At December 31, 2019, $59.7 million, or approximately 92%, of the net book value of our property, plant and equipment was located in the United States and $5.3 million, or approximately 8%, was located in India. At December 31, 2018, $42.9 million, or approximately 88%, of the net book value of our property, plant and equipment was located in the United States and $5.9 million, or approximately 12%, was located in India.